Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Financial Statements and Exhibits

11

Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Financial Statements and Exhibits

Item 9.01.

Financial Statements and Exhibits
(a) Financial Statements of the Business Acquired.
The audited financial statements of Otometrics for the year ended
December 31, 2015 and unaudited financial statements of Otometrics
for the six months ended June 30, 2016 as required by this Item
9.01(a) are attached as Exhibits 99.1 and 99.2 hereto,
respectively.
The Consent of Independent Auditors, issued by Ernst Young P/S,
dated March 20, 2017, relating to Otometrics’s audited financial
statements described above, is attached hereto in Exhibit 99.1.
(b) Pro forma financial information.
The unaudited pro forma financial statements for the Company, after
giving effect to the acquisition of Otometrics and adjustments
described in such pro forma financial statements, is attached
hereto as Exhibit 99.3.
(c) Exhibits.
Exhibit No.
Description
23.1
Consent of Independent Auditor, Ernst Young P/S.
99.1
Audited combined financial statements of Otometrics as of
and for the year ended December 31, 2015 and the notes
related thereto.
99.2
Unaudited condensed combined financial statements of
Otometrics as of and for the six month period ended June
30, 2016.
99.3
Unaudited pro forma balance sheet and unaudited pro forma
statement of income as of and for the year ended December
31, 2016.


About Natus Medical Incorporated (NASDAQ:BABY)

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.

Natus Medical Incorporated (NASDAQ:BABY) Recent Trading Information

Natus Medical Incorporated (NASDAQ:BABY) closed its last trading session up +0.65 at 38.95 with 516,316 shares trading hands.

An ad to help with our costs